Motoharu Sasaki1,2, Hitoshi Ikushima3, Masahide Tominaga3, Takeshi Kamomae4, Taro Kishi5, Masataka Oita6, Masafumi Harada7. 1. Department of Radiological Technology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan. msasaki@tokushima-u.ac.jp. 2. Department of Radiology and Radiation Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan. msasaki@tokushima-u.ac.jp. 3. Department of Therapeutic Radiology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan. 4. Department of Therapeutic Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, Aichi, 466-8550, Japan. 5. Department of Radiological Technology, Tokushima University Hospital, 2-50-1 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan. 6. Graduate School of Health Science, University of Okayama, 2-5-1 Shikata-cho, Okayama Kita-ku, Okayama, 700-8558, Japan. 7. Department of Radiology and Radiation Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8503, Japan.
Abstract
PURPOSE: In this study, we compared the dose impact of the heterogeneity caused by rectal gas using two methods of treatment planning for intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT). MATERIALS AND METHODS: In addition to the structure set used for the standard treatment plan, we created a structure set for evaluation for each patient. These sets were transferred to the same isocenter as the respective treatment plans for IMRT and VMAT that were to become the standard. Values were then recalculated. RESULTS: During the standard prostatic IMRT and VMAT treatment planning, all study participants met dose restrictions in place at our hospital. Dose restrictions were fulfilled in treatment plans for evaluation, excluding those with a clinical target volume (CTV) of V(100%) and planning target volume (PTV) of D95 when the rectum was excluded. However, in treatment plans for evaluation, IMRT was shown to have a higher concordance rate with standard treatment plans than VMAT. CONCLUSION: If rectal gas is present during either IMRT or VMAT, a dose decrease will occur in relation to CTV and PTV, suggesting that a plan does not eliminate adverse effects on organs at risk.
PURPOSE: In this study, we compared the dose impact of the heterogeneity caused by rectal gas using two methods of treatment planning for intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT). MATERIALS AND METHODS: In addition to the structure set used for the standard treatment plan, we created a structure set for evaluation for each patient. These sets were transferred to the same isocenter as the respective treatment plans for IMRT and VMAT that were to become the standard. Values were then recalculated. RESULTS: During the standard prostatic IMRT and VMAT treatment planning, all study participants met dose restrictions in place at our hospital. Dose restrictions were fulfilled in treatment plans for evaluation, excluding those with a clinical target volume (CTV) of V(100%) and planning target volume (PTV) of D95 when the rectum was excluded. However, in treatment plans for evaluation, IMRT was shown to have a higher concordance rate with standard treatment plans than VMAT. CONCLUSION: If rectal gas is present during either IMRT or VMAT, a dose decrease will occur in relation to CTV and PTV, suggesting that a plan does not eliminate adverse effects on organs at risk.
Authors: Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-31 Impact factor: 7.038
Authors: Patrick A Kupelian; Katja M Langen; Omar A Zeidan; Sanford L Meeks; Twyla R Willoughby; Thomas H Wagner; Sam Jeswani; Kenneth J Ruchala; Jason Haimerl; Gustavo H Olivera Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-01 Impact factor: 7.038
Authors: M J Zelefsky; D Crean; G S Mageras; O Lyass; L Happersett; C C Ling; S A Leibel; Z Fuks; S Bull; H M Kooy; M van Herk; G J Kutcher Journal: Radiother Oncol Date: 1999-02 Impact factor: 6.280
Authors: James R Wong; Lisa Grimm; Minoru Uematsu; Reva Oren; Chee Wai Cheng; Scott Merrick; Peter Schiff Journal: Int J Radiat Oncol Biol Phys Date: 2005-02-01 Impact factor: 7.038
Authors: M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel Journal: Radiother Oncol Date: 2000-06 Impact factor: 6.280
Authors: Katja M Langen; Twyla R Willoughby; Sanford L Meeks; Anand Santhanam; Alexis Cunningham; Lisa Levine; Patrick A Kupelian Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-14 Impact factor: 7.038